55
In band
Moving averages
SMA 200$12.59+1.99%
Company profile
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
SectorHealthcare
IndustryBiotechnology
Market cap$1.68B
P/E ratioNone
EPS$-3.34
Beta1.794
Dividend yield0.00%
52-week high$28.25
52-week low$7.95
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 79
VRTX
Vertex Pharmaceuticals Inc
RSI 67
CRSP
CRISPR Therapeutics AG
RSI 67
IOVA
Iovance Biotherapeutics Inc
RSI 72
MRNA
Moderna Inc
RSI 72
VKTX
Viking Therapeutics Inc
RSI 48
SRPT
Sarepta Therapeutics Inc
RSI 59
EDIT
Editas Medicine Inc
RSI 57
NVAX
Novavax Inc
RSI 63
DNA
Ginkgo Bioworks Holdings Inc - Class A
RSI 46
RSI alerts for NTLA
Get an email the moment Intellia Therapeutics Inc crosses into oversold or overbought territory. Nothing else, ever.
Add alertData last updated 12 August 2026 at 9:10 PM EDT